Inhibition of Notch signaling may cause growth inhibition of GSCs [44], which we believed was a possible mechanism underlying Vastatin’s anti-glioma effect and distinguished Vastatin from traditional antiangiogenic agents. This evidence concerns the gene COL8A1 and central nervous system cancer.